|
WO2021081411A1
|
|
Methods and compositions for treating irritable bowel syndrome and functional dyspepsia
|
|
WO2021026021A1
|
|
Methods of administering anti-siglec-8 antibodies and corticosteroids
|
|
WO2020168271A1
|
|
Methods and compositions for treating mast cell gastritis, mast cell esophagitis, mast cell enteritis, mast cell duodenitis, and/or mast cell gastroenteritis
|
|
KR20210005245A
|
|
Methods and compositions for treating chronic urticaria
|
|
US2021054072A1
|
|
Anti-siglec-7 antibodies having reduced effector function
|
|
EP3618872A1
|
|
Methods and compositions for treating inflammatory gastrointestinal disorders
|
|
WO2018204868A1
|
|
Methods and compositions for treating allergic ocular diseases
|
|
EP3565597A1
|
|
Methods and compositions for treating chronic obstructive pulmonary disorder
|
|
CN109790223A
|
|
Anti- SIGLEC-7 antibody for treating cancer
|
|
US2017114138A1
|
|
Methods and compositions for treating systemic mastocytosis
|
|
AU2016278239A1
|
|
Methods and compositions for treating fibrotic diseases
|
|
US2017073413A1
|
|
Methods and compositions for treating Siglec-8 associated diseases
|
|
BR112016013109A2
|
|
anti-siglec-8 antibodies and methods of use
|
